BiotechTube

ASP7962 + Naproxen + Placebo

Phase 2Completed
2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoarthritis of the Knee

Conditions

Osteoarthritis of the Knee, Chronic Lower Back Pain

Trial Timeline

Feb 16, 2016 → Sep 29, 2017

NCT ID
NCT02611466

About ASP7962 + Naproxen + Placebo

ASP7962 + Naproxen + Placebo is a phase 2 stage product being developed by Astellas Pharma for Osteoarthritis of the Knee. The current trial status is completed. This product is registered under clinical trial identifier NCT02611466. Target conditions include Osteoarthritis of the Knee, Chronic Lower Back Pain.

What happened to similar drugs?

20 of 20 similar drugs in Osteoarthritis of the Knee were approved

Approved (20) Terminated (1) Active (0)
✅NISEDr. Reddy's LaboratoriesApproved
✅Duloxetine + Sugar pillEli LillyApproved
✅Capsaicin Topical SolutionAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅ImrecoxibJiangsu Hengrui MedicineApproved
✅Etoricoxib (Arcoxia) + Sugar pillMerckApproved
✅zoledronic acidNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02611466Phase 2Completed

Competing Products

20 competing products in Osteoarthritis of the Knee

See all competitors
ProductCompanyStageHype Score
NISEDr. Reddy's LaboratoriesApproved
40
NISELATDr. Reddy's LaboratoriesPre-clinical
23
Duloxetine + PlaceboEli LillyPhase 3
40
LY2828360 + PlaceboEli LillyPhase 2
35
Investigational Medical Product (IMP) administered in parent studyEli LillyPhase 3
40
Duloxetine + Sugar pillEli LillyApproved
43
UBX0101 or placeboUnity BiotechnologyPre-clinical
8
UBX0101Unity BiotechnologyPhase 1
19
UBX0101Unity BiotechnologyPhase 2
25
UBX0101Unity BiotechnologyPhase 1
19
YH23537 + Celecoxib + YH23537 placeboYuhanPhase 2
35
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
Capsaicin Topical SolutionAstellas PharmaApproved
43
CGS-200-1 + CGS-200-5 + CGS-200 VehicleAstellas PharmaPhase 2
35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + PlaceboSun PharmaceuticalPhase 2
35
Duloxetine + PlaceboShionogiPhase 3
40
DuloxetineShionogiPhase 3
40
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part DOno PharmaceuticalPhase 1
29
ONO-4474 + Placebo matching ONO-4474Ono PharmaceuticalPhase 2
27
Duloxetine + PlaceboEli LillyPhase 3
40